

1 **Experiences and attitudes towards Menstrual Suppression among Women with Bacterial**  
2 **vaginosis Randomised to Continuous Use of NuvaRing in Kenya**

3 **Authors**

4 Edinah Casmir MA<sup>1</sup>, Njeri Wairimu BA<sup>1</sup>, Catherine Kiptinness MPH<sup>1</sup>, Lynda Oluoch MPH,  
5 MBChB<sup>1</sup>, Stephen Gakuo Maina MSc<sup>2</sup>, Kristina Wilbekin Walker<sup>3</sup>, Nelly Mugo MBChB,  
6 MMed<sup>1,4</sup>, Jeanne Marrazzo MD, MPH<sup>5</sup>, Kenneth Ngure PhD, MSc, MPH<sup>6</sup>

7  
8 **Author Affiliation**

9 <sup>1</sup>Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya

10 <sup>2</sup>African Population and Health Research Center

11 <sup>3</sup>Department of Epidemiology, School of Public Health, University of Alabama at Birmingham,  
12 Birmingham, AL, USA

13 <sup>4</sup>Department of Global Health, University of Washington, Seattle, WA, USA

14 <sup>5</sup>Department of Infectious Diseases, University of Alabama at Birmingham Heersink School of  
15 Medicine, Birmingham, AL, USA

16 <sup>6</sup>School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi,  
17 Kenya

18 **Corresponding Author**

19 Edinah Casmir\_ Research Scientist

20 Kenya Medical Research Institute

21 Tel: +254711944654

22 Email: [ednyab@gmail.com](mailto:ednyab@gmail.com)/ [ecasmir@kemri.go.ke](mailto:ecasmir@kemri.go.ke)/ [ecasmir@pipsthika.org](mailto:ecasmir@pipsthika.org)

23 [Orchid ID: 0000-0001-9568-721X](https://orcid.org/0000-0001-9568-721X)

24

25 **Abstract**

26 **Background:** The contraceptive vaginal ring (NuvaRing), one of the Multipurpose Prevention  
27 Technologies (MPT) products, is effective in preventing unintended pregnancies and may  
28 contribute to reducing the frequency of Bacterial Vaginosis (BV), which is a risk factor for  
29 HIV acquisition, transmission, and shedding among women. NuvaRing may cause irregular  
30 menstruation, including menstrual suppression, which may influence women's decision on  
31 product choice, use, and acceptability. In this prospective cohort study, we assessed women's  
32 experiences with menstruation suppression following continued NuvaRing use.

33  
34 **Methods:** A total of 18 in-depth interviews were conducted using a semi-structured interview  
35 guide among purposively selected women with BV in Thika, Kenya, aged 18-40 years, who  
36 used NuvaRing continuously. All women received counseling on possibility of menstrual  
37 suppression following continuous NuvaRing use. Audio recordings were transcribed verbatim  
38 and thematically analyzed.

39  
40 **Results:** Participants who expected and were aware that menstrual suppression was a possible  
41 side effect of Nuvaring accepted its benefits, and expressed acceptance and desire to continue  
42 using NuvaRing. Participants who had not anticipated menstrual suppression expressed anxiety  
43 and fear, with some expressing desire to continue using NuvaRing but worried about  
44 unintended negative consequences. The ability to perform daily activities uninterrupted,  
45 reduced expenses on sanitary supplies, enhanced sexual pleasure and relationships, and  
46 absence of menstrual pain were benefits of menstrual suppression. Although all participants  
47 received counseling on menstrual suppression, some expressed anxiety over the possibility of

48 unintended pregnancy. As a result, they frequented medical facilities for health check-ups and  
49 pregnancy tests, and some used combined oral contraceptives to induce menses.

50

51 **Conclusion:** Understanding perceptions regarding menstrual suppression is crucial in offering  
52 targeted and comprehensive counseling to improve women's understanding of menstruation  
53 suppression to influence acceptance and use of NuvaRing. Additionally, improved male  
54 involvement in reproductive health concerns and women's autonomy in discussing  
55 reproductive health issues with partners is essential.

56

57 **Key Words**

58 Menstrual suppression; experiences; attitudes; Contraceptive vaginal ring (CRV); Bacterial  
59 vaginosis; NuvaRing; Multipurpose Prevention Technologies

60

## 61 **Introduction**

62 Women of reproductive age in sub-Saharan Africa (SSA) are faced with the double burden of  
63 risk for human immunodeficiency virus (HIV) and unintended pregnancy (1,2). Although a  
64 decline in new Human Immunodeficiency Virus (HIV) infections has been observed in this  
65 region, women account for more than half (51%) of the HIV burden (1,2) with an estimation  
66 prevalence of 6.6 % in Kenya which is twice that of men (3.1%) (3,4). This is despite the efforts  
67 to improve access to the HIV prevention technologies including pre-exposure prophylaxis (PrEP)  
68 and condoms among others (1,5). Reasons for lack and/or low uptake of these interventions  
69 could be associated with stigma, gendered differences in relationships, lack of female-initiated  
70 products, low PrEP coverage, and non-adherence with the use of the available prevention  
71 technologies. This situation calls for preventive technologies that could address the double  
72 burden and the challenges in using the products that are currently available (1,6–9).

73 Multipurpose Prevention Technologies (MPT) addresses the double burden of unintended  
74 pregnancy and sexually transmitted infections (STI) including HIV in reproductive age women  
75 (10). In SSA, bacterial vaginosis (BV) is found in more than 55% of women and is a substantial  
76 risk factor for HIV acquisition in, transmission to male partners from, HIV infected women, and  
77 genital HIV shedding (11,12). Pregnancy is also an independent risk factor of HIV transmission  
78 and acquisition and therefore contraception provides biomedical prevention for women with or at  
79 risk of HIV (10). The contraceptive vaginal ring (NuvaRing), a hormonal contraceptive vaginal  
80 ring containing estrogen and progesterone, recently introduced in Kenya, is effective in  
81 preventing pregnancy and may contribute to reducing frequency of BV, and HIV shedding  
82 among HIV infected women, however, it may result in irregular menstruation including  
83 menstrual suppression (6,7).

84 Menstruation is a normal physiological process that is surrounded by a variety of socio-cultural  
85 beliefs that may influence women's decision-making on use of products that affect their  
86 menstrual bleeding, such as long or short duration, heavy or light, or suppression of menses (13–  
87 17). Menstruation is perceived as a process of cleansing the body by getting out the menstrual  
88 blood that is perceived to be 'dirty blood' (13–15,17). Literature shows that menstruation  
89 impacts on women's daily activities, including work, school, and sexual relationships among  
90 others. Although menstruation suppression is somehow acceptable (13,18–20), literature shows  
91 that menstrual suppression is perceived to cause a build-up of "dirty" or "blocked" blood, which  
92 is in turn perceived as causing blood clots, fibroids, emotional disturbances, weight gain,  
93 infertility, or death (13,14,17,18).

94 A variety of social-cultural factors may influence menstrual suppression perceptions (14–16).  
95 Literature indicates little understanding and recognition of how social, cultural, interpersonal,  
96 and individual beliefs, values, and perceptions influence menstrual suppression perception and  
97 its influences on acceptability, willingness to use, and actual use of biomedical interventions  
98 (8,13–16,18,20). Understanding the end-user experiences and how they may influence  
99 acceptability and willingness to use novel prevention technologies is essential among  
100 researchers, policymakers, and service providers for informing decisions about product  
101 development and formulation, roll-out, counselling, awareness, and marketing (6–8,13,19,21).  
102 Therefore, it is crucial to understand how end-user experiences may affect acceptance and  
103 willingness to use NuvaRing, depending on its impact on hormonal changes that may ultimately  
104 cause changes in the women's menstrual cycle, resulting in menses suppression. This paper  
105 explores how women's experiences, perceptions and attitudes of menstrual suppression with  
106 continuous use of the NuvaRing may influence its acceptability and use in Kenyan women.

## 107 **Methods**

### 108 **Study population and setting**

109 A qualitative sub-study was conducted between May 2017 to February 2018, nested within a  
110 randomised clinical trial that aimed to determine the effects of the NuvaRing on the vaginal  
111 microbiome and BV, HIV shedding and local immunity (clinicalTrials.gov Identifier:  
112 NCT02445989). This trial, conducted at Thika Partners Study Clinic (Partners in Health  
113 Research and Development), in Central Kenya, enrolled 121 women aged 18-40 years with BV  
114 based on clinical criteria (Amsel's criteria). Women were either HIV-infected and not on  
115 antiretroviral therapy (ART) according to Kenya ART guidelines or HIV-uninfected and, not  
116 intending to become pregnant during the study period, did not have any contraindications to  
117 hormonal contraceptive, specifically to contraceptive vaginal ring as well as capable of providing  
118 written informed consent. The participants were enrolled between April 2016 and November  
119 2017 and randomized to continuous or cyclical NuvaRing use, with a 6-month follow-up period.  
120 However, those who accepted the alternate hormonal contraception offered at month 7 were  
121 followed up for an additional month. Women were counselled on pregnancy prevention, and,  
122 HIV prevention if HIV-uninfected; condoms were provided to the participants throughout the  
123 study. Since menstrual suppression is likely to occur among continuous users of NuvaRing,  
124 women randomised in the continuous use arm and who had used the ring for at least 2 months  
125 were interviewed to understand their experiences and attitudes towards menstrual suppression  
126 that might influence its acceptability and use among Kenyan women.

### 127 **Data collection**

128 A total of 18 in-depth interviews (IDIs) were conducted using semi-structured interview guides  
129 aimed at identifying participants' experiences with continuous use of NuvaRing. Topics included

130 menstrual experiences over time, changes in menstruation before and after use of NuvaRing and  
131 participants thoughts about the changes, as well as perceptions towards menstrual suppression  
132 with NuvaRing use. Women who consented to qualitative interviews at enrolment and were  
133 willing to be interviewed to share their menstrual experiences over time with continuous use of  
134 the NuvaRing were approached to participate in the interviews. Interviews were conducted in  
135 English and Kiswahili, and audio-recorded by trained behavioural scientists in the participants’  
136 preferred language at a private location.

### 137 **Data analysis**

138 Audio recordings were transcribed verbatim, with Kiswahili Interviews simultaneously translated  
139 to English as needed. All transcripts were reviewed by behavioural scientists to ensure  
140 consistency and clarity, then uploaded to Dedoose Version 9.0.17 (Los Angeles, CA, USA), a  
141 web-based analysis application tool, for coding. The research team developed themes that guided  
142 development of a codebook through inductive and deductive approaches. Data were coded by  
143 two behavioural scientists after inter-coder agreement was reached. Output for specific themes  
144 (excerpts) were used to describe the study findings.

### 145 **Ethical considerations**

146 Ethical approval was obtained from Kenya Medical Research Institute’s Scientific Review  
147 committee and Ethics Review Board (SERU). All participants gave written informed consent to  
148 participate in the study. Women and men who were unable to read or write and expressed  
149 interest in the study were offered to have the consent read to them with a witness present. All  
150 study materials were labelled with a unique identifier to prevent participants from being  
151 individually recognized by staff.

152 **Results**

153 Findings from this study revealed that most participants experienced menstrual suppression with  
154 continuous use of NuvaRing. Some participants experienced suppression before and after using  
155 NuvaRing, while others experienced suppression only after NuvaRing use. A few participants  
156 experienced suppression before joining the study but did not experience it with continuous  
157 NuvaRing use, while others had never experienced suppression in their lifetime. Participants who  
158 experienced suppression before joining the study associated it to the side effects of using  
159 contraception such as depo, implants and combined oral contraceptives. Some attributed it to  
160 changes in climate, diet and stress.

161 Most participants reported that some women experience menstrual suppression naturally in their  
162 lifetime, while others intentionally suppressed their menses using combined oral contraception.  
163 Some women intentionally induce their menses by taking combined contraceptives, blue (dye),  
164 and drinking concentrated tea leaves. A few respondents did not know the cause of menses  
165 suppression. Notably, menstrual suppression surprised the majority of participants, despite  
166 knowing about it or having received counseling about it from providers.

167 Findings revealed that menstrual suppression was perceived in two different ways with most  
168 participants expressing positive attitudes, and a few expressed negative attitudes. The study  
169 findings are as summarised in the following themes, (i) perceived causes of menstrual  
170 suppression, (ii) positive attitudes towards menstrual suppression with continuous use of the  
171 NuvaRing, (iii) negative attitudes towards menstrual suppression with continuous use of the  
172 NuvaRing and (iv) male sexual partners' perceptions on menstrual suppression.

173

174

## 175 **Perceived causes of menstrual suppression**

176 Concerns related to menstrual suppression were not only limited to NuvaRing, because majority  
177 of the participants' perception on major causes of menses suppression included contraception use  
178 including depot-medroxyprogesterone acetate (DMPA), emergency contraceptive pills,  
179 intrauterine device (IUD), and combined contraceptive pills. Additionally, they mentioned that  
180 stress, sickness, blood donations, changes in diet and climate can result to menses suppression. A  
181 few of the participants did not know the cause of menses suppression despite having received  
182 counseling on the possibility of menses suppression with continuous use of NuvaRing by the  
183 study staff.

184 *“We can say mostly it suppresses when one starts using family planning which affects*  
185 *hormones. The first one is Depo, the second is this one called Jadelle. Those are the one*  
186 *that I know mostly suppresses. Stress can cause that (suppression), sometimes change of*  
187 *climate” (IDI 09)*

188 *“When I had exams, I had stress and panic and menses didn't come the following day so*  
189 *I knew stress can cause that (suppression). Yes, to others, it depends with one's*  
190 *hormones.” (IDI 07)*

## 191 **Positive attitudes towards menstrual suppression with continuous use of the NuvaRing**

192 Some of the positive attitudes included ability to run daily activities uninterrupted, reduced  
193 expenses on sanitary supplies, improved sexual experience and relationships, reduced menstrual  
194 pain, blood loss, worries and odour as a result of menstruation especially those who experienced  
195 heavy menses.

196 Most participants who experienced menstrual suppression liked that it resulted in reduction of  
197 menstrual pain which enabled them to engage in their daily activities without pain unlike before.

198 *“I feel okay that I don’t have the pain. I felt happy because in the past, before I got*  
199 *inserted the ring, I used to be moody, weak and with adnominal pain and heavy*  
200 *bleeding” (IDI 06)*

201 *“I like staying without menses because you know it is stressful, maybe you are at work or*  
202 *any other place and then you start having backache and abdominal pain; and you don’t*  
203 *have restrictions in movement” (IDI 01)*

204 In addition, their self-esteem and comfort improved as they did not have worries and/or fears of  
205 soiling their clothes and therefore their movement was not restricted like they used to experience,  
206 before using NuvaRing, especially those who experienced heavy menses.

207 *“I just feel comfortable. In the past before I joined this clinic (joining the study) I could*  
208 *not wear a skirt, I had to wear a trouser so that I wear a pant and hot pant to hold but*  
209 *now I only have a skirt and pant on and I am comfortable.” (IDI 06)*

210 Some participants liked menses suppression because it reduced blood loss and odour they  
211 experienced during menses before the use of NuvaRing. They said menstruation reduced blood  
212 levels, especially among people who experienced heavy menses. During menstruation, some  
213 participants had an odor that made them feel uncomfortable around people, but suppression made  
214 them to feel more comfortable and self-confident.

215 *“Yes, he knows (menses suppression). He used to complain about the discharge because*  
216 *it used to odour, so it got to a point that the discharge ended and he was happy, he even*  
217 *told the doctor that the ring is good when we came here.” (IDI 09)*

218 Further, a few participants were satisfied with menstrual suppression, and expressed desire to  
219 purchase the NuvaRing after the study because it allowed them to save money by eliminating the  
220 need to purchase on sanitary supplies including sanitary towels, soap and water to maintain  
221 personal hygiene when on menses. They felt the much money spent on sanitary supplies would  
222 rather be spent on something else.

223 *“You do not buy sanitary towels (laughing). You know in our place we buy water, so you*  
224 *don’t buy water often because you take a bath in the morning, afternoon and at night;*  
225 *you have to wash clothes and you have to buy soap. I will say that the ring is ok because I*  
226 *don’t feel what I used to feel in the past and it has helped me as I saved money (laughing)*  
227 *it is ok with me.” (IDI 06)*

228 *“I am free (laughing) ...from the stress of buying sanitary towels, and I save and the*  
229 *money for buying something else.” (IDI 07)*

230 Some participants experienced enhanced sexual satisfaction and relationships as their partners  
231 were happy because they could engage in sex whenever they wanted. Before suppression, some  
232 participants were uncomfortable engaging in sex during menses whenever their partners  
233 requested for it.

234 *“You know when I had menses, he was not happy but now when I don’t have, he is*  
235 *enjoying it every day (laughing).” (IDI 01)*

236 A few participants were not surprised with suppression of their menses because they were aware  
237 of menstrual suppression since they had been informed by the study staff of the possibility with  
238 NuvaRing use. They also received the information before joining the study from health providers  
239 in different health facilities, as well as from peers and other women in the community. Further,

240 some participants reported that they had experienced menstrual suppression prior to joining the  
241 study.

242 *“I was told I may, or I may not get menses so I waited knowing that I may or may not get*  
243 *menses. I usually don’t have a problem because when you have a man in the house is*  
244 *when you fear.” (IDI 15)*

245 *“I didn’t do a thing because before using the ring I used to use depo which suppresses*  
246 *menses, so I knew that.” (IDI 18)*

247 *“Aah... I had not messed so I was shocked because I didn’t know what was happening, so*  
248 *I thought it was the ring because when you are injected (depo) you miss menses. I just*  
249 *waited, and when I was almost to come here but I got my menses.” (IDI 11)*

## 250 **Negative attitudes towards menstrual suppression with continuous use of the NuvaRing**

251 Negative attitudes included possibility of unintended pregnancies, health conditions such as  
252 cervical cancer and hormonal imbalances; this prompted anxiety and fear resulting to hospital  
253 check-ups, and home-based self-pregnancy testing. Some participants expressed surprise and  
254 anxiety with menstrual suppression despite having experienced menstrual suppression before  
255 NuvaRing use and having had prior counselling/ knowledge/information on the possibility of  
256 menses suppression with the continuous use of the NuvaRing from study staff, health providers,  
257 peers and women in the community.

258 All participants apart from one reported the fear of possibility of unintended pregnancy and  
259 negative health consequences including infertility, hormonal imbalances, cancer, infections  
260 among others. When participants missed their menses they developed anxiety, fears and worries

261 of the likelihood of them having conceived because they knew that they had engaged in  
262 unprotected sex. This is because they felt that sometimes contraception might fail and end up  
263 conceiving, especially given that NuvaRing was new to a few of the participants. Some of the  
264 participants reported that they wondered what could have happened because they had not  
265 engaged in sex.

266 *“I thought I had become pregnant. That is the only thing that was disturbing me. I*  
267 *decided that the day I come here and get told that I am pregnant I will ask them why they*  
268 *inserted me the ring and it does not help me and tell them to take back their thing. I really*  
269 *felt bad because even when I was in the house, I used to feel I had a big problem*  
270 *(pregnancy) ahead of me.” (IDI 16)*

271 *“For now, I am used to, but there is a time I used to have stress. You cannot know, for*  
272 *example if I am with my husband I will not tell if the family planning has worked, or it*  
273 *has not worked so all the time there are fears of pregnancy.” (IDI 07)*

274 This resulted in participants visiting the study site and other health facilities for pregnancy tests  
275 and general inquiry on the cause of suppression. Some participants said that they were afraid  
276 because they did not know what was happening with their menses and/or their health and so they  
277 decided to visit the study site and health facilities for pregnancy test and consultation. A few  
278 participants decided to buy pregnancy test kits to carry out personalized pregnancy tests. After  
279 negative pregnancy tests, both by the study staff and personalized tests, and confirmation from  
280 the study staff that they did not have any health problem, some participants reported feeling  
281 comfortable, but a few participants said they always developed anxiety whenever they  
282 experienced suppression.

283 *“Aaah.... I had not messed (unprotected sex) so I was shocked because I didn’t know*  
284 *what was happening, so I thought it was the ring. I was not comfortable...when I came*  
285 *here and got explained to, I got comfortable”.* (IDI 11)

286 *“Ok, I was wondering because I missed my menses the time, I expected so I wondered*  
287 *and asked myself like could I be pregnant and yet I have a ring? I kept quiet but I went*  
288 *and bought a test kit and found that I was ok, so I waited.”* (IDI 04)

289 *“Mmmh...I was shocked a bit, but I said to myself that maybe they have delayed. I just*  
290 *went for a check-up, I asked, and I was told that they have delayed. I came here and they*  
291 *told me that I am ok.”* (IDI 02)

292 A few participants said that they did not like menstrual suppression since they did not know  
293 when to expect their menses. They reported that they had to keep their sanitary towels in their  
294 travelling bags so that they could easily access them if they received their menses unawares.

295 *“I was ok but I used to plan myself well like I had sanitary towels with me always when I*  
296 *am on journey because it can come when I am anywhere.”* (IDI 18)

297 *“I feel bad and bored because sometimes you carry sanitary towels every day and it does*  
298 *not come.”* (IDI 01)

299 These fears are informed by the community perception that if a woman does not get menses, then  
300 there is a likelihood that she is pregnant if she engages in sex, has hormonal imbalance or a  
301 health problem including infertility and that they are abnormal or bewitched and therefore they  
302 should not get married. Additionally, they said that women experience menses suppression  
303 usually develop big tummies/ bellies.

304           “...where I come from, we know that when one has menses you are not pregnant, and  
305           some say that if you don’t get menses then you can get like cancer.” (IDI 01)

### 306   **Male sexual partners’ perceptions on menstrual suppression**

307   The majority of the women reported that they did not disclose to their partners about their  
308   menstrual suppression because they are reserved discussing about their menses. However, 5 of  
309   the 18 women disclosed the use of NuvaRing and their menstrual suppression with their partners.  
310   One participant reported that her partner was supportive of the use of the NuvaRing because he  
311   did not like menses. A few participants said that their partners perceived menses suppression  
312   negatively because they believed it had negative effects on women’s health and therefore said  
313   that the NuvaRing was not good.

314           “*He was happy because he also doesn’t like it.....He knows I had planned (having*  
315           *contraception), and I came asked the doctor about it and I was told that missing menses*  
316           *is not bad because the ovaries are not there...so I explained to him so.” (IDI 01)*

317           “*He tells me that it (menstrual suppression) is caused by the things I use.” (IDI 03)*

### 318   **Discussion**

319   Findings revealed that while some women naturally experienced menstrual suppression, others  
320   intentionally suppressed their menses, and some women induced it after suppression. Most  
321   participants associated menstrual suppression with contraception use, infertility, hormonal  
322   imbalance, stress, blood donations, dietary changes, and environmental changes. Similar to  
323   reports from other studies, some participants were aware of menses suppression and its causes  
324   before and after joining the study (9,13–18,20), while others were unaware despite receiving  
325   regular menstrual suppression counseling and the possibility of suppression with continued

326 NuvaRing use. These findings highlight participants' different levels of knowledge/awareness on  
327 menses suppression highlighting the significance and need for continued comprehensive  
328 counselling on matters menstrual health and suppression.

329 Findings revealed that while some participants expressed positive attitudes concerning menstrual  
330 suppression with continued NuvaRing use, others had negative attitudes. These experiences and  
331 attitudes are worth considering because they may influence the acceptability and use of an  
332 intervention or product, in this case, NuvaRing. This finding is supported by existing literature  
333 (9,13-18,20) which show that different and varied needs, feelings, perceptions, beliefs, and  
334 knowledge/awareness based on individual, interpersonal, societal, and cultural values, norms and  
335 beliefs. In this study, participants with positive experiences expressed acceptance and a desire to  
336 continue using NuvaRing; however, those with negative attitudes had mixed emotions, with  
337 some expressing a desire to continue using NuvaRing but had fears of the unintended negative  
338 consequences. These findings have been found with the use of other products as well, such as  
339 contraception, other rings, and microbicides (13,13,18,22), showing the significance of end-user  
340 experiences in influencing the acceptability and use of an intervention or product, in this case,  
341 the NuvaRing.

342 Menstrual suppression was well received among participants who were aware of it, which is  
343 supported by findings from other studies (13, 9,20). Similar to these studies, participants  
344 expressed positive experiences such as ability to engage in daily activities uninterrupted,  
345 enhanced marital relationships resulting from sexual satisfaction, reduction of expenses on  
346 sanitary supplies and blood loss. Although racial and regional/ geographical differences in  
347 menses suppression exist globally, other studies have also shown that women are positive with  
348 menses suppression since it supports women's quality of life through improving convenience,

349 and avoiding negative menses related outcomes such as heavy and prolonged menses, nausea,  
350 bloating, fatigue and menstrual pain (13,19,20).

351 As other studies have shown, some participants reported negative experiences following menses  
352 suppression with a preference in non-suppression (13,18,22). Similar to these studies, we found  
353 that menstrual suppression caused worry, fear, and anxiety about unintended pregnancies, among  
354 negative health outcomes like infections, hormonal imbalances, and cancer. Existing literature  
355 demonstrate that contraceptives or ring users worry about future infertility and are uncertain  
356 about birth control effectiveness hence preventing their use or result in discontinuation  
357 (13,18,22). Although comprehensive counselling may not sufficient by itself, these concerns  
358 illustrate how crucial it is to understand the user pregnancy intentions among other concerns to  
359 support designing and providing complete counselling messages on use and adherence to avoid  
360 unintended consequences and support mental health (6,7,13–15,17,21,22).

361 Following pregnancy tests and a doctor's confirmation of no underlying health issues, the  
362 majority of participants felt at ease. However, like other studies (13,16,18,19,22), a few  
363 participants had persistent fear and anxiety whenever they missed menses, and uncertainty about  
364 when they expected menses disincentivizing them from NuvaRing use. These negative  
365 experiences may be associated with existing literature (16) that the community regarded women  
366 without menses as pregnant or infertile, abnormal, bewitched, or unhealthy. As indicated in other  
367 studies, results from this study demonstrate varied participants' knowledge of potential side  
368 effects of continued NuvaRing use on menses suppression, highlighting the importance of end-  
369 user regular tailored comprehensive counseling of an interventions use including side effects.  
370 This counseling should consider and align with individual and community levels of knowledge,

371 needs, feelings, perceptions and concerns to address potentially harmful or negative perceptions  
372 that may influence an intervention or product acceptability, use and adherence (6,7,17,18,22).  
373 Concerning male partners' awareness of menses suppression, most participants felt  
374 uncomfortable discussing their menses and hence did not inform their partners about their  
375 suppression (14,15), however, a few participants did. Male partners did not like NuvaRing,  
376 except for one who disliked menses. These findings similar to other studies illustrate the major  
377 role of male influence in acceptability and use of reproductive health interventions among  
378 women, and the importance of male partner involvement in matters reproductive health to bridge  
379 the gap between acceptability and actual use (6–9,13,18). Additionally, it shows the importance  
380 of empowering women's self-agency in discussing and disclosing matters reproductive health  
381 with their partners and male involvement in reproductive health matters to support and improve  
382 acceptability and use of new reproductive health interventions among women (6–9).

### 383 **Limitation**

384 Studies with a large cohort and a representative sample of participants including male partners  
385 selected from various geographic locations and communities in Kenya may explain and enrich  
386 these findings since the interviews only included a small number of participants and hence may  
387 not be generalized.

### 388 **Conclusion**

389 Exploring women's experiences with continuous NuvaRing use in relation to menstrual changes  
390 helps develop an understanding of how menstrual suppression may influence their decision-  
391 making and preference for NuvaRing use and adherence. In this study, some participants  
392 preferred continued NuvaRing use owing to the benefits that improved women's quality of life  
393 resulting from suppression, while others preferred non-suppression due to perceived unintended

394 health outcomes and considered it abnormal, thus did not wish to use NuvaRing. In addition,  
395 male partners did not like NuvaRing, except for one who disliked menses. These findings are  
396 pertinent in informing the development, marketing, roll-out, education/ awareness creation,  
397 designing tailored-comprehensive counselling for users during service delivery for future MPTs  
398 product or intervention for HIV/ STIs and pregnancy prevention. Additionally, the results  
399 highlight the significance of enhancing women's agency in discussions about reproductive health  
400 issues. Moreover, the study shows the importance of male involvement in reproductive health  
401 matters because of their crucial role in influencing reproductive health interventions or product  
402 use.

#### 403 **Informed Consent**

404 All participants provided written informed consent to participate in the study. Women and men  
405 who were unable to read or write and expressed interest in the study were offered to have the  
406 consent read to them with a witness present. All the study materials were labelled using a unique  
407 identifier.

#### 408 **Ethical approval**

409 All procedure performed in this study were in accordance with the ethical approval that was  
410 obtained from Kenya Medical Research Institute's Scientific Review committee and Ethics  
411 Review Board (SERU).

#### 412 **Acknowledgement**

413 We thank participants who took part in the study and the study staff at the KEMRI-CCR,  
414 (PHRD)Thika Project in Kenya for all of their hard work.

#### 415 **Authors Contribution**

416 NM, JM, and KN were involved in the study's conception, design, and funding. EC conducted  
417 the interviews, and two behavioral scientists (EC and NW) created a codebook based on the  
418 interview guide topics. EC and NW coded and reviewed the coded transcripts under KN's  
419 supervision. EC compiled the report with manuscript review support from NW, CK, LO, SGM,  
420 KWW, NM, JM, and KN. The manuscript was submitted by EC.

#### 421 **Funding**

422 The study was funded by the National Institutes of Health\_ National Institute of Child Health  
423 and Human Development (NIH-NICHD) award, grant number R01HD077872.

#### 424 **Conflict of Interest Declaration**

425 The authors declare no competing interests.

426

427

428

## 429 **References**

- 430 1. UNAIDS data 2021 [Internet]. [cited 2022 Aug 15]. Available from:  
431 [https://www.unaids.org/en/resources/documents/2021/2021\\_unaids\\_data](https://www.unaids.org/en/resources/documents/2021/2021_unaids_data)
- 432 2. Global HIV & AIDS statistics — Fact sheet [Internet]. [cited 2022 Aug 15]. Available from:  
433 <https://www.unaids.org/en/resources/fact-sheet>
- 434 3. Kenya’s National HIV Survey Shows Progress Towards Control of the Epidemic. Nairobi,  
435 20th February 2020 – MINISTRY OF HEALTH [Internet]. [cited 2022 Aug 15]. Available  
436 from: [https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towards-control-](https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towards-control-of-the-epidemic-nairobi-20th-february-2020/)  
437 [of-the-epidemic-nairobi-20th-february-2020/](https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towards-control-of-the-epidemic-nairobi-20th-february-2020/)
- 438 4. Kenya Preliminary Report 2018 [Internet]. PHIA Project. [cited 2022 Aug 15]. Available  
439 from: <https://phia.icap.columbia.edu/kenya-preliminary-report/>
- 440 5. WORLD AIDS DAY REPORT 2020.pdf | Powered by Box [Internet]. [cited 2022 Aug 15].  
441 Available from: <https://app.box.com/s/kb1f0tkbjhlc2a610too8vlpizxqla8>
- 442 6. Montgomery ET, Roberts ST, Reddy K, Tolley E, Hartmann M, Wilson E, et al. Integration  
443 of a Relationship-focused Counseling Intervention with Delivery of the Dapivirine Ring for  
444 HIV Prevention to Women in Johannesburg: Results of the CHARISMA Pilot Study. *AIDS*  
445 *Behav.* 2022 Mar 1;26(3):752–63.
- 446 7. Montgomery ET, Katz AWK, Duby Z, Mansoor LE, Morar NS, Naidoo K, et al. Men’s  
447 Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and  
448 Zimbabwe. *AIDS Behav.* 2021 Jun 1;25(6):1890–900.

- 449 8. Roberts ST, Nair G, Baeten JM, Palanee-Philips T, Schwartz K, Reddy K, et al. Impact of  
450 Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a  
451 Phase III HIV Prevention Trial. *AIDS Behav.* 2020 May 1;24(5):1432–42.
- 452 9. Pleasants E, Tauya T, Reddy K, Mirembe BG, Woeber K, Palanee-Phillips T, et al.  
453 Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN  
454 020/ASPIRE Trial. *AIDS Behav.* 2020 Mar 1;24(3):866–80.
- 455 10. Young Holt B, Turpin JA, Romano J. Multipurpose Prevention Technologies: Opportunities  
456 and Challenges to Ensure Advancement of the Most Promising MPTs. *Frontiers in*  
457 *Reproductive Health* [Internet]. 2021 [cited 2022 Aug 15];3. Available from:  
458 <https://www.frontiersin.org/articles/10.3389/frph.2021.704841>
- 459 11. Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, et al. Bacterial  
460 Vaginosis Associated with Increased Risk of Female-to-Male HIV-1 Transmission: A  
461 Prospective Cohort Analysis among African Couples. *PLOS Medicine.* 2012 Jun  
462 26;9(6):e1001251.
- 463 12. Bayigga L, Kateete DP, Anderson DJ, Sekikubo M, Nakanjako D. Diversity of vaginal  
464 microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention.  
465 *American Journal of Obstetrics and Gynecology.* 2019 Feb 1;220(2):155–66.
- 466 13. Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women's  
467 responses to contraceptive-induced menstrual bleeding changes. *Reproductive Health.* 2018  
468 Jun 26;15(1):114.

- 469 14. Duby Z, Katz A, Musara P, Nabukeera J, Zimba CC, Woeber K, et al. “The state of mind  
470 tells me it’s dirty”: menstrual shame amongst women using a vaginal ring in Sub Saharan  
471 Africa. *Women Health*. 2020 Jan;60(1):72–86.
- 472 15. Duby Z, Katz AWK, Browne EN, Mutero P, Etima J, Zimba CC, et al. Hygiene, Blood  
473 Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring  
474 During Menstruation in Malawi, South Africa, Uganda and Zimbabwe. *AIDS Behav*. 2020  
475 Feb;24(2):617–28.
- 476 16. Ghiasí A. The effect of gender-role orientation on attitudes towards menstruation in a sample  
477 of female university students. *J Turk Ger Gynecol Assoc*. 2019 Sep;20(3):138–41.
- 478 17. Laher F, Todd CS, Stibich MA, Phofa R, Behane X, Mohapi L, et al. Role of menstruation in  
479 contraceptive choice among HIV-infected women in Soweto, South Africa. *Contraception*.  
480 2010 Jun;81(6):547–51.
- 481 18. McLellan-Lemal E, Ondeng’o K, Gust D, Desai M, Otieno F, Madiega P, et al.  
482 Contraceptive vaginal ring experiences among women and men in Kisumu, Kenya: A  
483 qualitative study. *Front Womens Health*. 2017 Mar;2(1):10.15761/FWH.1000122.
- 484 19. Hillard PA. Menstrual suppression: current perspectives. *Int J Womens Health*. 2014 Jun  
485 23;6:631–7.
- 486 20. Trego LL, Jordan PJ. Military Women’s Attitudes Toward Menstruation and Menstrual  
487 Suppression in Relation to the Deployed Environment: Development and Testing of the  
488 MWATMS-9 (Short Form). *Women’s Health Issues*. 2010 Jul 1;20(4):287–93.

489 21. Todd CS, Stibich MA, Laher F, Malta MS, Bastos FI, Imbuki K, et al. Influence of culture  
490 on contraceptive utilization among HIV-positive women in Brazil, Kenya, and South Africa.  
491 AIDS Behav. 2011 Feb;15(2):454–68.

492 22. Leslie J, Kiweewa F, Palanee-Phillips T, Bunge K, Mhlanga F, Kamira B, et al. Experiences  
493 with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-  
494 Saharan Africa. BMC Women’s Health. 2021 Apr 23;21(1):175.

495